Antengene Publishes Preclinical Research on Combined Cancer Therapy

Antengene Corporation Limited has published a preclinical research paper examining the use of its CD73 small molecule inhibitor, ATG-037, in combination with selinexor for cancer treatment. The study focuses on the potential of this combination within cancer gene therapy.

The published research indicates that ATG-037, a small molecule inhibitor targeting the CD73 protein, may offer new therapeutic avenues for certain types of cancer when used alongside selinexor. These preclinical findings are significant for future development.

Antengene is focused on the discovery, development, and commercialization of innovative medicines, aiming to provide first-in-class and/or best-in-class therapies for challenging diseases.

The research outcomes support the company's strategy of developing combination therapies that could potentially improve patient responses and outcomes.